Company / Working Capital
Anika Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$81.5M
FY2025
5-year range
$81.5M / $141.6M
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 3 consecutive years, from $142M in FY2022 to $81M in FY2025.
Based on SEC 10-K filings.
$81M in FY2025 with a 5-year CAGR of -17.9%.
Declined from $132M to $81M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -16.8%
- 5-Year CAGR
- -17.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Anika Therapeutics, Inc.'s working capital has declined for 3 consecutive years.
- 5-year CAGR of -17.9%, indicating a declining trend.
- In FY2025, working capital decreased 9.8% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $81.5M | -9.8% |
| FY2024 | $90.3M | -31.7% |
| FY2023 | $132.3M | -6.6% |
| FY2022 | $141.6M | +2.1% |
| FY2021 | $138.7M | -36.4% |
| FY2020 | $218.0M | +0.0% |
| FY2019 | $218.0M | +13.8% |
| FY2018 | $191.7M | -0.8% |
| FY2017 | $193.3M | +19.6% |
| FY2016 | $161.6M | +1.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026